DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Proleukin (Aldesleukin) - Published Studies

 
 



Proleukin Related Published Studies

Well-designed clinical trials related to Proleukin (Aldesleukin)

The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. [2002.04]

Well-designed clinical trials possibly related to Proleukin (Aldesleukin)

Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion. [2011.02.01]

Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. [2010.02.23]

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. [2010.02.10]

Short-term preoperative IL-2 immunotherapy in operable pancreatic cancer: a randomized study. [2009.05]

Why patients continue to participate in clinical research. [2008.06.23]

Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. [2008.02]

A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). [2006.12.15]

Intravenous immunoglobulin plus interferon-alpha in autoimmune hepatitis C. [2004]

Regulatory approvals in a large multinational clinical trial: the ESPRIT experience. [2002.02]

Effects of interleukin-2 therapy on the proliferation and differentiation of CD4/CD25 positive and CD4/CD25 negative cells in HIV+ patients. [2001.07]

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2. [1998.11]

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. [1998.04.30]

Pancreatic resection for pancreatic carcinoma combined with neo- and adjuvant locoregional targeting immuno-chemotherapy--a prospective randomized study. [1998.03]

Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. [1997.11]

Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma. [1995.11]

Other research related to Proleukin (Aldesleukin)

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. [2009.08.01]

The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. [2009.08]

Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). [2008.07.01]

[Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma] [2008.02]

Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): geographical and gender differences in the baseline characteristics of participants. [2006.03]

Aldesleukin in advanced renal cell carcinoma. [2004.12]

Hypersensitivity to aldesleukin (interleukin-2 and proleukin) presenting as facial angioedema and erythema. [2003.07]

Toxicity management in patients receiving low-dose aldesleukin therapy. [1998.12]

High-dose aldesleukin in renal cell carcinoma: long-term survival update. [1997.12]

Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: evaluation of three methods. [1995.11.01]

Other possibly related research studies

Locoregional IL-2 low dose applications for gastrointestinal tumors. [2005.09.21]

Management of metastatic cutaneous melanoma. [2004.10]

Technology evaluation: BAY-50-4798, Bayer. [2004.04]

Transcutaneous IL-2 uptake mediated by Transfersomes depends on concentration and fractionated application. [2004.02.21]

Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. [2003.08]

Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. [2003]

Managing toxicities of high-dose interleukin-2. [2002.11]

Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. [2002.11]

Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma. [2002.12]

Therapeutic enhancement of IL-2 through molecular design. [2002]

[Persistent inflammatory reaction at the injection site of Il-2 with lymphoma-like inflammatory infiltrates] [2002.08]

Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapy. [2002.08]

Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. [2001]

Preoperative main portal branch transection combined with liver locoregional transarterial neo and adjuvant immunochemotherapy for patients with hepatocellular carcinoma. [2000.11]

A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. [2000.11]

Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. [2000.09]

Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Austrian Renal Cell Carcinoma Study Group. [2000.09]

High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma. [2000.05.01]

Management of renal cell carcinoma. [2000.01]

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. [1999.07]

Immunotherapy in renal cell carcinoma. [1999.06]

Interleukin-2 therapy for advanced chronic myeloid leukemia. [1998.11]

Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients. [1998.06]

Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study. [1998.03]

Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study. [1998.04]

Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma. [1997.08]

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. [1997.10.01]

Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma. [1996.11]

Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes). [1996.01.17]

Tumor-directed cytotoxicity in multiple myeloma--the basis for an experimental treatment approach with interleukin 2. [1995.08]

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. [1995.03]

[Peritumoral administered IL-2-induced tumor regression in melanoma. Pilot study] [1994.08]

Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: a pilot study. [1994]

Dualistic effects of cis-diammine-dichloro-platinum on the anti-tumor efficacy of subsequently applied recombinant interleukin-2 therapy: a tumor-dependent phenomenon. [1993.05.28]

Interleukin-2 increases the antibody response in patients receiving autologous intralymphatic tumor cell vaccine immunotherapy. [1992.06]

Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study. [1992.05]

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. [2004.08.16]

Anticancer drug-induced kidney disorders. [2001.01]

Treatment of malignant melanoma. [1999.06]

Hepatitis B vaccine: current issues. [1997.09]

Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. [1993.09]

Recombinant interleukin-2: a biological response modifier. [1991.02]

A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells. [2006.02.17]

Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. [1995.09]

Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study. [1992.11]

A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. [2006.12.01]

Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. [2006.10.01]

Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. [2007.06.01]

Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. [2007.08]

Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation. [2007.11.05]

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. [2008.04.22]

Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy. [2008.01.15]

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. [2008]

Advances in antiretroviral therapy. [2009.04]

Treatment of metastatic renal cell carcinoma. [2009.06]

Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. [2009.01]

Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice. [2010.09]

Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment. [2010.07.01]

Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. [2010.03.13]

Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. [2010.03.01]

Administration of high-dose interleukin-2 in a 2-year-old with metastatic melanoma. [2009.12.15]

Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2. [2009.09.15]

Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2. [2011.02]

Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. [2010]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012